1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Alligator Bioscience AB

Alligator Bioscience AB

0.01
SEK
0.00
(0.00%)
74.25MMarket Cap
Alligator Bioscience AB
STO:ATORX
(Nasdaq Stockholm)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
- -
107.17
21.21
17.47
8.27
1.34
1.52
3.6
6.65
5.33
1.91
0.02
- -
Revenue per Share
-24.01
76.69
-17.61
-19.58
-46.01
-64.44
-50.01
-39.38
-36.05
-22.79
-7.74
-1.87
- -
Basic EPS, GAAP
-20.88
75.02
-15.09
-34.96
-34.28
-56.21
-49.37
-35.31
-32.33
-17.58
-7.34
-5.77
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
21.43
124.13
207.37
189.51
143.62
79.28
35.34
31.88
10.06
0.74
-7.07
0.11
0.01
Book Value per Share
4.51
110.55
201.16
183.56
137.76
73.56
29.71
29.83
8.02
-0.38
-8.57
-0.51
-0.06
Tangible Book Value per Share
3
3
3
3
3
3
3
4
5
11
30
28
322
Basic Weighted Avg Shares
- -
290
58
57
27
4
4
13
36
58
58
1
- -
Sales/Revenue/Turnover
- -
69.36
-59.39
-108.98
-564.52
-4,891.49
-3,309.65
-1,101.85
-538.72
-429.19
-328.37
-23,669.26
- -
Operating Margin (%)
3
13
25
3
6
12
12
11
12
10
49
-10
- -
Depreciation Expense
-77
207
-48
-64
-150
-210
-143
-142
-193
-249
-234
-51
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
71.56
-83.03
-112.1
-556.58
-4,821.29
-3,292.65
-1,095.08
-541.81
-427.81
-404.89
-9,990.27
- -
Profit Margin (%)
12
351
652
508
378
165
80
252
58
-21
-130
-9
-17
Working Capital
- -
- -
- -
- -
- -
11
6
4
16
8
33
26
21
LT Debt
69
397
676
618
468
258
115
282
89
12
-131
7
3
Total Equity
- -
87.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
89.1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
89.1
-9.01
-9.85
-27.63
-57.82
-76.68
-71.31
-104.17
-492.71
- -
- -
- -
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
18
9
9
LT Borrowings
- -
- -
- -
LT Finance Leases
26
23
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
64
628
628
Market Capitalization
15
74
74

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
69
53
24
Cash, Cash Equivalents & STI
62
33
17
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
78
30
41
Payables & Accruals
- -
- -
- -
ST Debt
18
9
9
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-137.97%
-263.4%
-105.25%
Free Cash Flow
11.79%
4.84%
-28.35%
Net Income, GAAP
3.2%
-4.01%
-78.05%
Sales/Revenue/Turnover
11.75%
67.25%
-99.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7
8
1
42
58
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.92
-1.07
-1.41
-1.78
-7.74
2025
-0.54
-0.08
- -
-0.66
-1.87
2026
- -
-0.06
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Alligator Bioscience AB (publ) is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs for cancer treatment. The company specializes in agonist mono- and bispecific antibodies targeting immune pathways such as CD40 and 4-1BB to activate the patient's immune system within the tumor microenvironment; its lead product candidate is mitazalimab, a CD40-targeting agonist antibody in preparation for Phase 3 trials in first-line metastatic pancreatic cancer following positive Phase 2 OPTIMIZE-1 results showing unprecedented 24-month survival outcomes; additional pipeline assets include ATOR-1017, a 4-1BB agonist monoclonal antibody in Phase 1 for solid tumors; ALG.APV-527, a 4-1BB x 5T4 bispecific T-cell engager co-developed with Aptevo Therapeutics in Phase 1 for solid metastatic tumors; ATOR-4066, a preclinical tumor-directed bispecific using the Neo-X-Prime platform; and early-stage candidates from proprietary platforms ALLIGATOR-GOLD (human antibody library), ALLIGATOR-FAB (scaffolded Fab library), FIND (molecular evolution technology), and RUBY (bispecific format). Alligator operates primarily in Sweden and Finland with global partnerships, targeting high-unmet-need solid tumors through early-stage drug development up to Phase 2 clinical trials. Founded in 2001 and headquartered in Lund, Sweden, the company maintains collaborations including a 2021 research and license agreement with Orion Corporation for RUBY-based bispecifics, a 2017 co-development pact with Aptevo for ALG.APV-527, and agreements with BioArctic, MacroGenics, Biotheus, and Abclon (via subsidiary Atlas Therapeutics) for antibody technologies and licensed programs like AC101 in Phase 2 by Shanghai Henlius; recent developments encompass a rights issue announced October 2025 for SEK 120 million to fund 6-9 months of operations into 2026, February 2025 top-line data validating the 900 µg/kg mitazalimab dose for Phase 3, an August 2025 R&D event highlighting the pipeline, peer-reviewed publication of ATOR-1017 clinical data in January 2025, FDA Orphan Drug Designation, and a January 2024 US patent for ATOR-4066.